Bones, Hot Flashes and ADT: Using with Chemotherapy and Timing - Thomas Keane
September 1, 2017
Thomas Keane discusses strategies to mitigate side effects of androgen deprivation therapy (ADT) and the difference between intermittent versus continuous ADT. Dr. Keane focuses his lecture on the side effect of hot flashes while undergoing ADT therapy and recommendations for the management of hot flashes. Also, discussed is bone health and the acceleration of bone loss in men during ADT treatment.
Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Jehonathan Pinthus and Neal Shore
Watch: Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa- Christopher Sweeney
Watch: Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke
A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: A randomized controlled trial
Thomas E. Keane, MBBCh, FRCSI, FACS